{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T23:28:55Z","timestamp":1792970935763,"version":"4.5.0"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.intimp.2021.107933","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T19:15:45Z","timestamp":1625253345000},"page":"107933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":211,"special_numbering":"C","title":["TIM-3: An update on immunotherapy"],"prefix":"10.1016","volume":"99","author":[{"given":"Lizhen","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.intimp.2021.107933_b0005","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.intimp.2021.107933_b0010","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.intimp.2021.107933_b0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","article-title":"Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells","volume":"1","author":"Selby","year":"2013","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1016\/j.intimp.2021.107933_b0020","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.intimp.2021.107933_b0025","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.intimp.2021.107933_b0030","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"issue":"6871","key":"10.1016\/j.intimp.2021.107933_b0035","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"issue":"5853","key":"10.1016\/j.intimp.2021.107933_b0040","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1126\/science.1148536","article-title":"Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells","volume":"318","author":"Anderson","year":"2007","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.intimp.2021.107933_b0045","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1002\/eji.200939274","article-title":"TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines","volume":"39","author":"Hastings","year":"2009","journal-title":"Eur J Immunol"},{"issue":"12","key":"10.1016\/j.intimp.2021.107933_b0050","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat Immunol"},{"issue":"11","key":"10.1016\/j.intimp.2021.107933_b0055","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/ni987","article-title":"Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance","volume":"4","author":"Sanchez-Fueyo","year":"2003","journal-title":"Nat Immunol"},{"issue":"7","key":"10.1016\/j.intimp.2021.107933_b0060","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.4049\/jimmunol.180.7.4409","article-title":"Lack of TIM-3 immunoregulation in multiple sclerosis","volume":"180","author":"Yang","year":"2008","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.intimp.2021.107933_b0065","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.4049\/jimmunol.177.7.4281","article-title":"Preferential involvement of Tim-3 in the regulation of hepatic CD8+ T cells in murine acute graft-versus-host disease","volume":"177","author":"Oikawa","year":"2006","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.intimp.2021.107933_b0070","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1111\/j.1600-6143.2011.03727.x","article-title":"The emerging role of the TIM molecules in transplantation","volume":"11","author":"Yeung","year":"2011","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.intimp.2021.107933_b0075","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.immuni.2007.01.016","article-title":"T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface","volume":"26","author":"Cao","year":"2007","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.intimp.2021.107933_b0080","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.immuni.2007.01.014","article-title":"Structures of T Cell immunoglobulin mucin receptors 1 and 2 reveal mechanisms for regulation of immune responses by the TIM receptor family","volume":"26","author":"Santiago","year":"2007","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2021.107933_b0085","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jmb.2007.09.060","article-title":"Structural analysis of the human galectin-9 N-terminal carbohydrate recognition domain reveals unexpected properties that differ from the mouse orthologue","volume":"375","author":"Nagae","year":"2008","journal-title":"J Mol Biol"},{"issue":"1","key":"10.1016\/j.intimp.2021.107933_b0090","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunol Rev"},{"issue":"7","key":"10.1016\/j.intimp.2021.107933_b0095","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.4049\/jimmunol.170.7.3631","article-title":"Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway","volume":"170","author":"Kashio","year":"2003","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.intimp.2021.107933_b0100","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/hep.25777","article-title":"Tim-3\/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma","volume":"56","author":"Li","year":"2012","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.intimp.2021.107933_b0105","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.4049\/jimmunol.0903059","article-title":"T cell\/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells","volume":"184","author":"DeKruyff","year":"2010","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2021.107933_b0110","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.0105-2896.2010.00903.x","article-title":"TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity","volume":"235","author":"Freeman","year":"2010","journal-title":"Immunol Rev"},{"issue":"16","key":"10.1016\/j.intimp.2021.107933_b0115","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/blood-2008-10-185884","article-title":"Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation","volume":"113","author":"Nakayama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2021.107933_b0120","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3389\/fcell.2020.00648","article-title":"Loss of the Major Phosphatidylserine or Phosphatidylethanolamine Flippases Differentially Affect Phagocytosis","volume":"8","author":"Fazeli","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.intimp.2021.107933_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173095","article-title":"The apoptosis clearance signal phosphatidylserine inhibits leukocyte migration and promotes inflammation resolution in vivo","volume":"877","author":"Sordi","year":"2020","journal-title":"Eur J Pharmacol"},{"issue":"5674","key":"10.1016\/j.intimp.2021.107933_b0130","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1126\/science.1094359","article-title":"Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice","volume":"304","author":"Hanayama","year":"2004","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.intimp.2021.107933_b0135","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/nri957","article-title":"A blast from the past: clearance of apoptotic cells regulates immune responses","volume":"2","author":"Savill","year":"2002","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.intimp.2021.107933_b0140","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/ni.2376","article-title":"Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1","volume":"13","author":"Chiba","year":"2012","journal-title":"Nat Immunol"},{"issue":"9","key":"10.1016\/j.intimp.2021.107933_b0145","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/ni.2396","article-title":"Tumor immunity times out: TIM-3 and HMGB1","volume":"13","author":"Tang","year":"2012","journal-title":"Nat Immunol"},{"issue":"7534","key":"10.1016\/j.intimp.2021.107933_b0150","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature13848","article-title":"CEACAM1 regulates TIM-3-mediated tolerance and exhaustion","volume":"517","author":"Huang","year":"2015","journal-title":"Nature"},{"issue":"7616","key":"10.1016\/j.intimp.2021.107933_b0155","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nature17421","article-title":"Corrigendum: CEACAM1 regulates TIM-3-mediated tolerance and exhaustion","volume":"536","author":"Huang","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2021.107933_b0160","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.intimp.2016.12.024","article-title":"Co-expression of TIM-3 and CEACAM1 promotes T cell exhaustion in colorectal cancer patients","volume":"43","author":"Zhang","year":"2017","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"10.1016\/j.intimp.2021.107933_b0165","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3109\/03009742.2010.547871","article-title":"Expression of human TIM-3 and its correlation with disease activity in rheumatoid arthritis","volume":"40","author":"Lee","year":"2011","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"10.1016\/j.intimp.2021.107933_b0170","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1744-313X.2011.01046.x","article-title":"The -1541 C>T and +4259 G>T of TIM-3 polymorphisms are associated with rheumatoid arthritis susceptibility in a Chinese Hui population","volume":"38","author":"Xu","year":"2011","journal-title":"Int J Immunogenet"},{"key":"10.1016\/j.intimp.2021.107933_b0175","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.msard.2017.09.031","article-title":"The +4259A>C polymorphism of TIM-3 but not -1637C>T polymorphism of TIM-1 is associated with Multiple sclerosis in Isfahan population","volume":"18","author":"Pouladian","year":"2017","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1016\/j.intimp.2021.107933_b0180","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/iji.12264","article-title":"Association of TIM-1 5383\u20135397ins\/del and TIM-3 -1541C>T polymorphisms with multiple sclerosis in Isfahan population","volume":"43","author":"Mazrouei","year":"2016","journal-title":"Int J Immunogenet"},{"issue":"6","key":"10.1016\/j.intimp.2021.107933_b0185","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1084\/jem.20062093","article-title":"Th2-driven, allergen-induced airway inflammation is reduced after treatment with anti-Tim-3 antibody in vivo","volume":"204","author":"Kearley","year":"2007","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.intimp.2021.107933_b0190","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1182\/blood-2006-11-058800","article-title":"TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cells","volume":"110","author":"Nakae","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.intimp.2021.107933_b0195","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.humimm.2004.07.002","article-title":"The association of TIM-3 gene polymorphism with atopic disease in Korean population","volume":"65","author":"Chae","year":"2004","journal-title":"Hum Immunol"},{"issue":"11","key":"10.1016\/j.intimp.2021.107933_b0200","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.4049\/jimmunol.176.11.6411","article-title":"Cutting edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity","volume":"176","author":"Frisancho-Kiss","year":"2006","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.intimp.2021.107933_b0205","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2021.107933_b0210","doi-asserted-by":"crossref","first-page":"1889822","DOI":"10.1080\/2162402X.2021.1889822","article-title":"TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients","volume":"10","author":"Rakova","year":"2021","journal-title":"Oncoimmunology"},{"issue":"19","key":"10.1016\/j.intimp.2021.107933_b0215","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1128\/MCB.05297-11","article-title":"Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways","volume":"31","author":"Lee","year":"2011","journal-title":"Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.intimp.2021.107933_b0220","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/cmi.2009.5","article-title":"Blockade of Tim-3 pathway ameliorates interferon-gamma production from hepatic CD8+ T cells in a mouse model of hepatitis B virus infection","volume":"6","author":"Ju","year":"2009","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.intimp.2021.107933_b0225","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1743-422X-8-113","article-title":"Tim-3 expression on peripheral T cell subsets correlates with disease progression in hepatitis B infection","volume":"8","author":"Wu","year":"2011","journal-title":"Virol J"},{"issue":"5","key":"10.1016\/j.intimp.2021.107933_b0230","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/eji.201141852","article-title":"Blockade of Tim-3 signaling restores the virus-specific CD8(+) T-cell response in patients with chronic hepatitis B","volume":"42","author":"Wu","year":"2012","journal-title":"Eur J Immunol"},{"issue":"11","key":"10.1016\/j.intimp.2021.107933_b0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002984","article-title":"Tim-3-expressing CD4+ and CD8+ T cells in human tuberculosis (TB) exhibit polarized effector memory phenotypes and stronger anti-TB effector functions","volume":"8","author":"Qiu","year":"2012","journal-title":"PLoS Pathog"},{"issue":"18","key":"10.1016\/j.intimp.2021.107933_b0240","doi-asserted-by":"crossref","first-page":"9122","DOI":"10.1128\/JVI.00639-09","article-title":"Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells","volume":"83","author":"Golden-Mason","year":"2009","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.intimp.2021.107933_b0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087821","article-title":"Enhanced virus-specific CD8+ T cell responses by Listeria monocytogenes-infected dendritic cells in the context of Tim-3 blockade","volume":"9","author":"Ma","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.intimp.2021.107933_b0250","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1002\/eji.201344392","article-title":"Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells","volume":"44","author":"Gautron","year":"2014","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2021.107933_b0255","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.molimm.2013.11.001","article-title":"The Tim-3\/galectin-9 pathway involves in the homeostasis of hepatic Tregs in a mouse model of concanavalin A-induced hepatitis","volume":"58","author":"Ju","year":"2014","journal-title":"Mol Immunol"},{"issue":"2","key":"10.1016\/j.intimp.2021.107933_b0260","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/QAI.0b013e318285cf13","article-title":"HIV infection deregulates Tim-3 expression on innate cells: combination antiretroviral therapy results in partial restoration","volume":"63","author":"Finney","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"10.1016\/j.intimp.2021.107933_b0265","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1182\/blood-2008-02-142596","article-title":"Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells","volume":"113","author":"Klibi","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.intimp.2021.107933_b0270","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12825","article-title":"TIM-3: An emerging target in the liver diseases","volume":"91","author":"Zhao","year":"2020","journal-title":"Scand J Immunol"},{"issue":"10","key":"10.1016\/j.intimp.2021.107933_b0275","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-11-0096","article-title":"Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors","volume":"71","author":"Ngiow","year":"2011","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.intimp.2021.107933_b0280","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1136\/gutjnl-2014-307671","article-title":"Tim-3 fosters HCC development by enhancing TGF-beta-mediated alternative activation of macrophages","volume":"64","author":"Yan","year":"2015","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.intimp.2021.107933_b0285","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/0008-5472.CAN-13-1504","article-title":"VISTA is an immune checkpoint molecule for human T cells","volume":"74","author":"Lines","year":"2014","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.intimp.2021.107933_b0290","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/2326-6066.CIR-14-0072","article-title":"VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy","volume":"2","author":"Lines","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.intimp.2021.107933_b0295","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.580557","article-title":"Ligand-Receptor Interactions of Galectin-9 and VISTA Suppress Human T Lymphocyte Cytotoxic Activity","volume":"11","author":"Yasinska","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2021.107933_b0300","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","article-title":"Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy","volume":"12","author":"Yang","year":"2021","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.intimp.2021.107933_b0305","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J Exp Med"},{"issue":"17","key":"10.1016\/j.intimp.2021.107933_b0310","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","article-title":"Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia","volume":"117","author":"Zhou","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.intimp.2021.107933_b0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030676","article-title":"TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression","volume":"7","author":"Gao","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.intimp.2021.107933_b0320","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI59806","article-title":"IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma","volume":"122","author":"Yang","year":"2012","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.intimp.2021.107933_b0325","first-page":"8018","article-title":"Up-regulation of Tim-3 is associated with poor prognosis of patients with colon cancer","volume":"8","author":"Zhou","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"issue":"6","key":"10.1016\/j.intimp.2021.107933_b0330","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.7314\/APJCP.2013.14.6.3897","article-title":"Prognostic value of T cell immunoglobulin mucin-3 in prostate cancer","volume":"14","author":"Piao","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"10.1016\/j.intimp.2021.107933_b0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053834","article-title":"Tim-3 expression in cervical cancer promotes tumor metastasis","volume":"8","author":"Cao","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.intimp.2021.107933_b0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152830","article-title":"Correction: Tim-3 Expression in Cervical Cancer Promotes Tumor Metastasis","volume":"11","author":"Cao","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.intimp.2021.107933_b0345","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s00262-010-0910-5","article-title":"Genetic variations and haplotypes in TIM-3 gene and the risk of gastric cancer","volume":"59","author":"Cao","year":"2010","journal-title":"Cancer Immunol Immunother"},{"issue":"23","key":"10.1016\/j.intimp.2021.107933_b0350","doi-asserted-by":"crossref","first-page":"23478","DOI":"10.18632\/aging.202343","article-title":"Transforming growth factor beta type 1 (TGF-beta) and hypoxia-inducible factor 1 (HIF-1) transcription complex as master regulators of the immunosuppressive protein galectin-9 expression in human cancer and embryonic cells","volume":"12","author":"Selno","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"2","key":"10.1016\/j.intimp.2021.107933_b0355","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.immuni.2014.06.011","article-title":"Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells","volume":"41","author":"Wu","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2021.107933_b0360","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40364-020-0185-8","article-title":"Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML","volume":"8","author":"Tan","year":"2020","journal-title":"Biomark Res"},{"issue":"8","key":"10.1016\/j.intimp.2021.107933_b0365","doi-asserted-by":"crossref","first-page":"7951","DOI":"10.1007\/s13277-014-2080-0","article-title":"Tim-3 expression is increased on peripheral T cells from diffuse large B cell lymphoma","volume":"35","author":"Xiao","year":"2014","journal-title":"Tumour Biol"},{"issue":"5","key":"10.1016\/j.intimp.2021.107933_b0370","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1111\/ajco.13033","article-title":"Increased exhausted CD8(+) T cells with programmed death-1, T-cell immunoglobulin and mucin-domain-containing-3 phenotype in patients with multiple myeloma","volume":"14","author":"Tan","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"issue":"3","key":"10.1016\/j.intimp.2021.107933_b0375","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.4049\/jimmunol.0903275","article-title":"Tim-3\/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells","volume":"185","author":"Dardalhon","year":"2010","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.intimp.2021.107933_b0380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058006","article-title":"Tim-3 expression defines regulatory T cells in human tumors","volume":"8","author":"Yan","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.intimp.2021.107933_b0385","doi-asserted-by":"crossref","DOI":"10.4161\/onci.23849","article-title":"TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer","volume":"2","author":"Sakuishi","year":"2013","journal-title":"Oncoimmunology"},{"issue":"7","key":"10.1016\/j.intimp.2021.107933_b0390","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s00262-019-02465-y","article-title":"Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes","volume":"69","author":"Zahran","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.intimp.2021.107933_b0395","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18030645","article-title":"TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action","volume":"18","author":"Du","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.intimp.2021.107933_b0400","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1084\/jem.20081398","article-title":"Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection","volume":"205","author":"Jones","year":"2008","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.intimp.2021.107933_b0405","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/eji.201242768","article-title":"HCV-infected hepatocytes drive CD4+ CD25+ Foxp3+ regulatory T-cell development through the Tim-3\/Gal-9 pathway","volume":"43","author":"Ji","year":"2013","journal-title":"Eur J Immunol"},{"issue":"3","key":"10.1016\/j.intimp.2021.107933_b0410","article-title":"Correction: Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages","volume":"11","author":"Staff","year":"2015","journal-title":"PLoS Pathog"},{"issue":"16","key":"10.1016\/j.intimp.2021.107933_b0415","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1182\/blood-2011-11-392951","article-title":"Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity","volume":"119","author":"Ndhlovu","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.intimp.2021.107933_b0420","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/imm.12463","article-title":"MicroRNA-155 regulates interferon-gamma production in natural killer cells via Tim-3 signalling in chronic hepatitis C virus infection","volume":"145","author":"Cheng","year":"2015","journal-title":"Immunology"},{"issue":"13","key":"10.1016\/j.intimp.2021.107933_b0425","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2011-06-360321","article-title":"Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9","volume":"119","author":"Gleason","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.intimp.2021.107933_b0430","doi-asserted-by":"crossref","first-page":"7660","DOI":"10.4049\/jimmunol.181.11.7660","article-title":"Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions","volume":"181","author":"Nagahara","year":"2008","journal-title":"J Immunol"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921005695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921005695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T15:13:25Z","timestamp":1730819605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921005695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":86,"alternative-id":["S1567576921005695"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107933","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TIM-3: An update on immunotherapy","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107933","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107933"}}